14-3-3theta protects against neurotoxicity in a cellular parkinson's disease model through inhibition of the apoptotic factor Bax

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Slone, Sunny R ^a   Lesort, Mathieu ^b   Yacoubian, Talene A ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CASPASE 3; CYTOCHROME C; NEUROPROTECTIVE AGENT; PROTEIN 14 3 3; PROTEIN 14 3 3 THETA; PROTEIN BAX; ROTENONE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; NEUROTOXIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG TARGETING; ENZYME ACTIVATION; ENZYME RELEASE; GENE OVEREXPRESSION; IMMUNOPRECIPITATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY;

CAENORHABDITIS ELEGANS;

14-3-3 PROTEINS; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROTOXINS; PARKINSON DISEASE; ROTENONE; SIGNAL TRANSDUCTION;

EID: 79960607222     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021720     Document Type: Article

References (47)

1. Porter GW, Khuri FR, Fu H, (2006) Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 16: 193-202.
2. Dougherty MK, Morrison DK, (2004) Unlocking the code of 14-3-3. J Cell Sci 117: 1875-1884.
3. Mackintosh C, (2004) Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J 381: 329-342.
4. Kawamoto Y, Akiguchi I, Nakamura S, Honjyo Y, Shibasaki H, et al. (2002) 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 61: 245-253.
5. Berg D, Riess O, Bornemann A, (2003) Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol 54: 135.
6. Athanassiadou A, Voutsinas G, Psiouri L, Leroy E, Polymeropoulos MH, et al. (1999) Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet 65: 555-558.
7. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
8. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
9. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
10. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
11. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
12. Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, et al. (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J 25: 211-221.
13. Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, Asteris G, McLean PJ, et al. (2008) Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis 29: 515-528.
14. Yacoubian TA, Slone SR, Harrington AJ, Hamamichi S, Schieltz JM, et al. (2010) Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death Dis 1: e2.
15. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ, (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628.
16. Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, et al. (2003) 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 278: 2058-2065.
17. Samuel T, Weber HO, Rauch P, Verdoodt B, Eppel JT, et al. (2001) The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem 276: 45201-45206.
18. Qi XJ, Wildey GM, Howe PH, (2006) Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281: 813-823.
19. Gill MB, Perez-Polo JR, (2009) Bax shuttling after rotenone treatment of neuronal primary cultures: effects on cell death phenotypes. J Neurosci Res 87: 2047-2065.
20. Smaili SS, Hsu YT, Sanders KM, Russell JT, Youle RJ, (2001) Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential. Cell Death Differ 8: 909-920.
21. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, et al. (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 2837-2842.
22. Lee do Y, Lee KS, Lee HJ, Noh YH, Kim do H, et al. (2008) Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur J Cell Biol 87: 389-397.
23. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, et al. (2004) JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23: 1889-1899.
24. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, et al. (2000) 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6: 41-51.
25. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M, (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13: 1407-1420.
26. King TD, Jope RS, (2005) Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 16: 597-601.
27. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, et al. (1991) Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 88: 3671-3675.
28. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, et al. (2007) Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12: 887-896.
29. Adams JM, Cory S, (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19: 488-496.
30. Hsu YT, Youle RJ, (1997) Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 272: 13829-13834.
31. Hsu YT, Youle RJ, (1998) Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 273: 10777-10783.
32. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615-622.
33. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, et al. (1999) Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284: 339-343.
34. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, et al. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430: 405-413.
35. Li X, Wang QJ, Pan N, Lee S, Zhao Y, et al. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6: e17153.
36. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430: 393-404.
37. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, et al. (2006) Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60: 197-203.
38. Firestone JA, Smith-Weller T, Franklin G, Swanson P, Longstreth WT Jr, et al. (2005) Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 62: 91-95.
39. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S, (2000) A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 21: 435-440.
40. Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, et al. (2009) Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 66: 1106-1113.
41. Yacoubian TA, Standaert DG, (2009) Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 1792: 676-687.
42. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22: 404-420.
43. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
44. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, et al. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22: 7006-7015.
45. Tatton NA, (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166: 29-43.
46. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, et al. (2005) Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 102: 19126-19131.
47. Perier C, Bove J, Wu DC, Dehay B, Choi DK, et al. (2007) Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A 104: 8161-8166.